Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RXRX
- Price
- 4.51
- Stock movement down
- -0.14 (-3.01%)
- Company name
- Recursion Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.72B
- Ent value
- 1.50B
- Price/Sales
- 26.42
- Price/Book
- 3.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -50.38%
- 3 year return
- -14.12%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RXRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.42 |
| Price to Book | 3.28 |
| EV to Sales | 22.96 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 381.90M |
| EPS (TTM) | -1.34 |
| FCF per share (TTM) | -1.18 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 65.18M |
| Gross profit (TTM) | 1.96M |
| Operating income (TTM) | -404.37M |
| Net income (TTM) | -377.58M |
| EPS (TTM) | -1.34 |
| EPS (1y forward) | -1.65 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 3.01% |
| Operating margin (TTM) | -620.35% |
| Profit margin (TTM) | -579.26% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 427.65M |
| Net receivables | 2.25M |
| Total current assets | 474.17M |
| Goodwill | 52.06M |
| Intangible assets | 34.09M |
| Property, plant and equipment | 0.00 |
| Total assets | 726.50M |
| Accounts payable | 2.26M |
| Short/Current long term debt | 90.63M |
| Total current liabilities | 108.89M |
| Total liabilities | 201.94M |
| Shareholder's equity | 524.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -317.82M |
| Capital expenditures (TTM) | 14.81M |
| Free cash flow (TTM) | -332.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -71.98% |
| Return on Assets | -51.97% |
| Return on Invested Capital | -69.79% |
| Cash Return on Invested Capital | -61.48% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.60 |
| Daily high | 4.63 |
| Daily low | 4.07 |
| Daily Volume | 27.1M |
| All-time high | 41.33 |
| 1y analyst estimate | 9.86 |
| Beta | 0.80 |
| EPS (TTM) | -1.34 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| RXRX | S&P500 | |
| Current price drop from All-time high | -89.09% | -14.41% |
| Highest price drop | -90.39% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -71.41% | -11.07% |
| Avg time to new high | 77 days | 12 days |
| Max time to new high | 942 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.72B
Marketcap category
Small-cap
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Employees
500
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page